DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

Our STN: BL 103795/5359

JUN 2 8 2008

Amgen, Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799

Attention: Carol Waldo, M.P.H., R.A.C.
Director, Regulatory Affairs

Dear Ms. Waldo:

Please refer to your supplemental biologics license application dated December 3, 2007, received December 4, 2007, submitted under section 351 of the Public Health Service Act for Enbrel® (etanercept).

We acknowledge receipt of your submissions dated December 19, 2007, January 29, and June 6, 2008.

This supplemental biologics license application provides for conversion of the Patient Information Sheet to a Medication Guide in response to our November 2, 2007 supplement request letter.

We have completed our review of this application and it is approved, effective on the date of this letter, for use as recommended in the enclosed content of labeling [CFR 601.14(b)] in structured product labeling (SPL) format.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format as described at http://www.fda.gov/oc/datacouncil/spl.html that is identical to the attached labeling and Medication Guide. Upon receipt, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission, "**SPL for approved BLA 103795/5359**."

We acknowledge your December 19, 2007 submission containing final printed carton and container labels.

Marketing the product with labeling that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

RISK EVALUATION AND MITIGATION STRATEGIES (REMS) REQUIREMENTS

Title IX, Subtitle A, Section 901 of the Food and Drug Administration Act of 2007 (FDAAA) amends the Federal Food, Drug, and Cosmetic Act (FDCA) to authorize FDA to require the submission of a Risk Evaluation and Mitigation Strategy (REMS) for an approved drug if the Secretary becomes aware of new safety information and makes a determination that such a strategy is necessary to ensure that the benefits of the drug outweigh the risks (section 505-1(a)(2)). This provision took effect on March 25, 2008.

Since Enbrel was approved in 1998, FDA has become aware of new safety information, as defined in FDAAA. This new safety information shows that serious infections, including tuberculosis, have occurred in patients taking Enbrel. Some patients have died from these serious infections.

In accordance with section 505-1 of the FDCA, as one element of a REMS, FDA may require the development of a Medication Guide as provided for under 21 CFR Part 208. Pursuant to 21 CFR Part 208, FDA has determined that Enbrel poses a serious and significant public health concern requiring distribution of a Medication Guide. The Medication Guide is necessary for patients' safe and effective use of Enbrel. FDA has determined that Enbrel is a product that has serious risks of which patients should be made aware because information concerning the risks could affect patients' decisions to use Enbrel. Under 21 CFR 208, you are responsible for ensuring that the Medication Guide is available for distribution to patients who are dispensed Enbrel.

Your proposed REMS is approved. The REMS consists of the Medication Guide included with this letter and the timetable for submission of assessments of the REMS included in your May 20, 2008 electronic submission. The timetable you submitted is as follows:

1st FDAAA assessment:	November 2009 (18 months from approval)
2nd FDAAA assessment:	May 2011 (3 years from approval)
3rd FDAAA assessment:	May 2015 (7 years from approval)

Information needed for assessment of the REMS should include but may not be limited to:

a. A survey of patients' understanding of the serious risks of Enbrel.
b. A report on periodic assessments of the distribution and dispensing of the Medication Guide in accordance with 21 CFR 208.24.
c. A report on failures to adhere to distribution and dispensing requirements, and corrective actions taken to address noncompliance.

For administrative purposes, all submissions related to this REMS must be clearly designated "**Risk Evaluation and Mitigation Strategy (REMS)**."

LETTER TO HEALTH CARE PROFESSIONALS

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this BLA and a copy to the following address:

MEDWATCH
Food and Drug Administration
5515 Security Lane
HFD-001, Suite 5100
Rockville, MD 20852

Please refer to http://www.fda.gov/cder/biologics/default.htm for information regarding therapeutic biological products, including the addresses for submissions.

This information will be included in your biologics license application file.

If you have any questions, call Tanya Clayton, Regulatory Project Manager, at (301) 796-0871.

Sincerely,

Bob Rappaport, M.D.
Director
Division of Anesthesia, Analgesia
And Rheumatology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure: Medication Guide
Package Insert
Carton and Container label